SLC18A2 and Parkinson disease: This study demonstrates the concurrence of three prevalent non-motor symptoms with clear reduced VMAT2 levels in disease-associated brain regions, suggesting an increased likelihood that these patients have preclinical/prodromal parkinsonism.